Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study

Journal of the American College of Cardiology

Volumn 43, Issue 8, 2004, Pages 1423-1429

  Rouleau, Jean L ^a,m   Roecker, Ellen B ^b   Tendera, Michal ^c   Mohacsi, Paul ^d   Krum, Henry ^e   Katus, Hugo A ^f   Fowler, Michael B ^g   Coats, Andrew J S ^h   Castaigne, Alain ⁱ   Scherhag, Armin ^j   Holcslaw, Terry L ^k   Packer, Milton ^l  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF BERN   (Switzerland)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k GLAXOSMITHKLINE   (United States)

^l Columbia University ^*  (United States)

^m NONE   (Canada)

more..

Author keywords

ACE; Angiotensin converting enzyme; Blood pressure; BP; Carvedilol Prospective Randomized Cumulative Survival trial; CHF; Chronic heart failure; COPERNICUS; Heart failure; HF; SBP; Systolic blood pressure

Indexed keywords

AMIODARONE; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CARBAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 11144358541     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.037     Document Type: Article

References (14)

1. for the U.S.Carvedilol Heart Failure Study Group, Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
2. The CIBIS-II Investigators and Committees. The Cardiac Insufficiency BIsoprolol Study II (CIBIS-II). Lancet. 353:1999;9-13.
3. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (merit-hf). Lancet. 353:1999;2001-2007.
4. for the Carvedilol Prospective Randomized Cumulative Survival Study Group, Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
5. Gaffney T.E., Braunwald E. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 34:1963;320-324.
6. Sackner-Bernstein J., Krum H., Goldsmith R.L., et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment (abstr)? Circulation. 92:(Suppl I):1995;I395.
7. Waagstein F., Caidahl K., Wallentin I., Bergh C., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy Effects of short- and long-term metoprolol treatment followed by withdrawal and re-administration of metoprolol. Circulation. 80:1989;551-563.
8. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 106:2002;2194-2199.
9. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
10. Physician's Desk Reference. Prescribing Information. Tenormin I.V. injection (atenolol). Thompson, 2004.
11. Canesin M.F., Giorgi D., de Oliveira M.T., et al. Ambulatory blood pressure monitoring of patients with heart failure A new prognosis marker. Arq Bras Cardiol. 78:2002;83-89.
12. Franciosa J.A., Wilen M., Ziesche S., et al. Survival in men with severe chronic left ventricular failure due to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 51:1983;831-836.
13. Cleland J.G.F., Dargie H.J., Ford I. Mortality in heart failure Clinical variables of prognostic value. Br Heart J. 58:1987;572-582.
14. Ghali J.K., Kadakia S., Bhatti A., et al. Survival of heart failure patients with preserved versus impaired systolic function The prognostic implication of blood pressure. Am Heart J. 123:1992;993-997.